Interleukin-1Graphic Secretion. A POSSIBLE MULTISTEP PROCESS THAT IS REGULATED IN A CELL TYPE-SPECIFIC MANNER (*)

  1. William M. Siders and
  2. Steven B. Mizel(§)
  1. From the (1)Department of Microbiology and Immunology, Wake Forest University Medical Center, Winston-Salem, North Carolina 27157
  1. § To whom correspondence and reprint requests should be addressed. Tel.: 910-716-4471; Fax: 910-716-9928.

Abstract

In a prior study, we found that the processed form of human interleukin-1β (mature IL-1β) is secreted to a significantly greater extent than the precursor form of the protein, indicating that the precursor domain acts in some manner to reduce the secretory potential of the protein. In view of this observation, we sought to define the sequence(s) in the IL-1β precursor that limit the secretion of the protein as well as the sequences in the mature protein that promote secretion. The P388D1 murine macrophage cell line and the Jurkat human T-cell line were transiently transfected with cDNA expression vectors encoding truncated forms of human precursor IL-1β proteins, lacking either the first 76, 94, 99, or 104 amino acids. The removal of increasing numbers of precursor amino acid residues resulted in a graded increase in the secretion of the truncated precursor IL-1β proteins from both cell lines. The minimal region of the precursor sequence required to inhibit the optimal secretion of IL-1β occurs between amino acids 100 and 104 for P388D1 cells and 95-99 for Jurkat cells. Deletion of the amino acids within these regions increased the secretion level of the truncated proteins to that of mature IL-1β. Mutagenesis of the mature IL-1β sequence revealed that a region of basic amino acids may play an important role in the optimal secretion of mature IL-1β in P388D1 cells, but not in Jurkat cells. Based on the differences in the structural requirements for IL-1β secretion in P388D1 and Jurkat cell lines, it is likely that the secretion of IL-1β may be subject to multiple levels of regulation that are differentially operative in different cell types.

Footnotes

  • * This work was supported by National Institutes of Health Grant AI25836 and National Institutes of Health Training Grant AI07401 (to W. M. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • 1 The abbreviations used are:

    IL

    interleukin

    PCR

    polymerase chain reaction

    RSV

    Rous sarcoma virus.

  • 2 U. Kavita and S. B. Mizel, unpublished observations.

  • 3 W. M. Siders and S. B. Mizel, unpublished observations.

« Previous | Next Article »Table of Contents
  • Advertisement
  • Advertisement
Advertisement